Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Febuxostat - Teijin Pharma

Drug Profile

Febuxostat - Teijin Pharma

Alternative Names: Adenuric; Feburic; Febuxostat XR; TEI-6720; TMX 67XR; TMX-67; TMX-67HK; TURAZIVE; Uloric

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teijin Pharma
  • Developer Astellas Pharma; Ipsen; Menarini; SK Chemicals; Takeda Pharmaceuticals USA; Te Arai BioFarma; Teijin Pharma
  • Class Antigouts; Carboxylic acids; Ischaemic heart disorder therapies; Nitriles; Phenyl ethers; Small molecules; Thiazoles; Uricosurics
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout; Hyperuricaemia
  • Registered Tumour lysis syndrome
  • Suspended Angina pectoris

Most Recent Events

  • 26 Jun 2023 Registered for Gout (In children) in Japan (PO)
  • 26 Jun 2023 Registered for Hyperuricaemia (In children) in Japan (PO)
  • 01 Jun 2022 Efficacy data from a phase IIIb CARES trial for Hyperuricaemia (in patients with gout and cardiovascular co-morbidities) presented at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top